TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2893.
Locate Jan Aushadhi KendraClinical Overview
Prednisolone (Dispersible Tablets 20mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Disperse tablet in a glass of water (5-10 ml) until fully dissolved and swallow immediately, preferably with or after breakfast in the morning. Morning administration aligns with physiological circadian cortisol rhythm and minimizes hypothalamic-pituitary-adrenal (HPA) axis suppression.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Short-term: Insomnia, mood changes, increased appetite, facial flushing, dyspepsia. Long-term / High-dose: Iatrogenic Cushingoid features (moon face, buffalo hump, central adiposity), osteoporosis/fractures, hyperglycemia/steroid-induced diabetes, hypertension, increased susceptibility to infections, peptic ulceration, skin thinning, and growth retardation in children.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Sudden cessation causes acute adrenal insufficiency; gradual tapering is mandatory. Contraindicated in systemic fungal infections, live viral vaccinations, and active untreated tuberculosis. Caution in peptic ulcer disease, diabetes mellitus, osteoporosis, hypertension, and glaucoma.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.
Prednisolone Tablets 5 mg
Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.
Prednisolone Tablets 10 mg
Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.
Gatifloxacin 0.3 % w/v + Prednisolone 1% w/v Eye Drops
Prednisolone Acetate / Sodium Phosphate (1% w/v eye drops) is the gold-standard topical ophthalmic corticosteroid on the WHO Model List of Essential Medicines. It delivers high corneal and intraocular penetration, suppressing cellular infiltration, capillary dilatation, fibroblast proliferation, and collagen deposition in the anterior segment. Indicated for steroid-responsive ocular inflammation (anterior uveitis, post-operative cataract inflammation, severe allergic blepharoconjunctivitis, and corneal graft rejection prophylaxis).
Prednisolone Sodium Phosphate Eye Drops 1%w/v
Prednisolone Acetate / Sodium Phosphate (1% w/v eye drops) is the gold-standard topical ophthalmic corticosteroid on the WHO Model List of Essential Medicines. It delivers high corneal and intraocular penetration, suppressing cellular infiltration, capillary dilatation, fibroblast proliferation, and collagen deposition in the anterior segment. Indicated for steroid-responsive ocular inflammation (anterior uveitis, post-operative cataract inflammation, severe allergic blepharoconjunctivitis, and corneal graft rejection prophylaxis).